Quantumup Posted - 2 days ago

Jefferies raised the price target on $NBIX to $182 was $180/Buy: ‘‘NBIX toplined +'ve Ph2 MDD data for NBI-'845 (AMPA potentiator) w efficacy comparable to Ph3 esketamine & AE profile comparable to pbo (no mention of dissociation & seizure, we're keeping an eye on pot'l dizziness). While Qs remain on how efficacy holds up (given the lack of dose response for other drugs + shrinking effect sizes from Ph.2 to Ph.3), we view '845 as nice upside and increase our PS to $425M w/ 35% POS that brings up our PT to $182.’’ $jnj $bmy $krtx cere $abbv

Market_Max Posted - 3 days ago

@calbucs for real context, look at $KRTX that was recently acquired by BMS for over $13B. BMY didn't buy KRTX before the 1st P3 data came out; didn't buy KRTX after the 1st P3 data came out positive. Didn't even buy until well before the company was ready to submit the goddam NDA. So Y'all really need to get grounded and stay even keel or y'all will just keep getting your blood to boil for a long long time. There's still a lot of risk ahead that Y'all have no clue about. SAVA is a highly speculative bet until the 1st P3 data is positive!.

Night_Owl_Biotech Posted - 1 week ago

$MDGL trades at 16% of total 10-year analyst consensus revenues estimates. Peers acquired a year before to a year after FDA approval, including $MYOK $KRTX $RETA were acquired at 38 to 81% of their total 10-year revenue estimates (as prepared by management per subsequent 14A/14D9 filings). The attachment notes the enterprise values paid 5 companies acquired a year before or after FDA approval compared to management's revenue forecasts. We did not include Viela Bio acquired 8 months after FDA approval (at the peak of the $XBI). We're struggling to understand the disconnect. Rezdiffra is a pill so we'd assume gross manufacturing margins consistent with peer pill manufacturers. MDGL consensus revenue estimates are per Seeking Alpha. Any guidance would be appreciated. Perhaps it is because the M&S efforts would be more significant in NASH (at least versus the peers). As always, this is not investment advice. Thank you.

11thestate Posted - 1 week ago

$KRTX shareholder drops proposed class action following Bristol-Myers Squibb's $14 billion acquisition.

ItSaulGoodMaan Posted - 3 weeks ago

$VKTX You folks didn't think this was simply gonna consolidate awaiting eventual buyout without some rats cleaning you out of your shares with this endless volatility. Even $KRTX had days and months where it kept dumping for no reason before the sale. Stock like this you buy and fucking forget about until you hear about it on the news. Only a fool sells on a day like today.

Cal1f0rn1aBay Posted - 1 month ago

$KRTX $SPLK $AYX $CBAY $BKCC

RobRit Posted - 1 month ago

$KRTX $NWRPH Jeff Yass is on board

RobRit Posted - 1 month ago

$KRTX #NWRPH make a DD and buy Newron. Evenamide is the New Blockbuster in Schizophrenie

HaltTradeAlert Posted - 1 month ago

$KRTX Halt Time: 19:50:00 Issue Symbol: KRTX Reason Code: T12 Stock Price: $329.83 Market Cap: 12.599B Volume: 1,283,005 Relative Volume: 1.33 Shares Float: 36.27M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

tradethehalt Posted - 1 month ago

$KRTX trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $329.83 Vol: 1.87M.

HaltTradeAlert Posted - 1 month ago

$KRTX Halt Time: 19:50:00 Issue Symbol: KRTX Reason Code: T12 Stock Price: $329.83 Market Cap: 12.582B Volume: 1,808,160 Relative Volume: 1.91 Shares Float: 36.27M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

tomRussell80 Posted - 1 month ago

$krtx last trading day today. still $.16 spread.

CTFNLighthouse Posted - 1 month ago

$KRTX $BMY Bristol-Myers Squibb has received HSR approval for its proposed acquisition of Karuna Therapeutics. The transaction is expected to close as early as March 18, subject to the satisfaction or waiver of remaining closing conditions.

ElijahJobs Posted - 1 month ago

$ACAD Shows how tough it is to meet the primary ends of the clinical trials for negative symptoms of schizophrenia... $NERV should not feel bad about its recent CRL. $BMY could be the only one with a viable candidate for the symptoms now that it recently acquired $KRTX. JMO

jayslow Posted - 1 month ago

$TSVT WO $KRTX: $KURA ,$GEHC, $BMY

insiderbuyingselling Posted - 1 month ago

$KRTX new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=KRTX

Thestocktraderhubzee Posted - 1 month ago

$KRTX HC Wainwright & Co. Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target

smartkarma Posted - 1 month ago

$KRTX | Karuna Therapeutics: Is The Bidding Battle Underway? "I see a strong wave of M&A activity in neuropsychiatry space and think the risk/reward of owning KRTX shares is favorable despite the substantial premium of the BMY-KRTX deal" - Andrei Zakharov Key Points: * In December 2023, American multinational pharmaceutical company Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $330 per share in cash, implying a total equity value of $14B. * The special meeting of Karuna’s shareholders to be held on March 12, 2023, to consider and vote on various proposals necessary to approve upcoming M&A deal. * I expect the bidding battle among big pharma to acquire Karuna Therapeutics and its valuable pipeline of transformative medicines to treat schizophrenia and psychosis in Alzheimer’s disease. Read more: https://www.smartkarma.com/insights/karuna-therapeutics-is-the-bidding-battle-underway

canthistrendtoday Posted - 1 month ago

$AKBA look at this one's coming $VTXB $CBAY $KRTX

HeyyVern Posted - 1 month ago

$vktx $krtx $akro these kind of stocks are a joke. 5 years of zero revenue. 1000 percent speculative price squeezes all based on buyout trial results. Tell me you're a shell company without telling me you're a shell company.

Positivecashflow83 Posted - 02/29/24

$KRTX well at 12bil mk, and being bought out for under that figure, looks like its down hill from here

Mahnur Posted - 2 months ago

$KRYS vs $KRTX

Night_Owl_Biotech Posted - 2 months ago

The attached graph compares the revenue estimates prepared by $IMGN, $RETA & $KRTX per their respective 14A filings to $ITCI analyst consensus revenue estimates through the year 2032. The graph then assumes ITCI annual sales growth of 2.0% for the year 2033 thru Caplyta patent expiration in 8/2039. Analysts forecast ITCI to generate more revenues than RETA & IMGN as prepared by RETA & IMGN management. If valuations are predicated on anticipated future revenues, does this mean ITCI warrants a higher valuation in a theoretical M&A transaction? We do not know the answer. Our next post will compare gross margin forecasts from 14A filings compared to ITCI (using ITCI's actual FY2023 gross margin profile at 92.7%). The gross margin graph looks more or less like the attached sales graph here. We own ITCI so we have every motive to see ITCI trade higher. It is also possible the graphs are inaccurate as we've made mistakes before. As always, do your own due diligence.

epsguid Posted - 2 months ago

$KRTX reported a loss of $3.01, consensus was ($2.64) via @eWhispers #epsmiss http://eps.sh/d/krtx

DonCorleone77 Posted - 2 months ago

$KRTX $BMY Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65) In December 2023, Karuna (KRTX) and Bristol Myers Squibb (BMY) announced they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14B, or $12.7B net of estimated cash acquired. The Boards of Directors of both companies have unanimously approved the transaction. The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval of Karuna stockholders and receipt of required regulatory approvals.

Stock_Titan Posted - 2 months ago

$KRTX Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update https://www.stocktitan.net/news/KRTX/karuna-therapeutics-reports-fourth-quarter-and-full-year-2023-17iqyersdkm1.html

swingingtech Posted - 2 months ago

$PSIL, $BMY, $KRTX, $ACHC https://wallstreetwaves.com/mental-health-mavericks-3-stocks-changing-the-game/

insiderbuyingselling Posted - 2 months ago

$KRTX new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=KRTX

Quantumup Posted - 2 months ago

UBS🏁 $AXSM Buy/$111~is bullish on Auvelity's launch/ $AXSM' pipeline opps w/ upcoming late-stage clinical readouts. UBS est $2.4B rev '29. Auvelity could become a leading brand in depression, generating $1B by '30. +VE P3 AD/narcolepsy data should drive stock OP. $krtx $bmy $cere $abbv

CTFNLighthouse Posted - 2 months ago

$KRTX $BMY Karuna Therapeutics filed a definitive proxy statement for its proposed acquisition by Bristol-Myers Squibb. Target shareholders are scheduled to vote at 9am ET on March 12. Regulatory conditions: HSR was initially filed on January 8. On February 2, the parties pulled their notification from the US Department of Justice’s Antitrust Division and the US Federal Trade Commission; they plan to refile on February 12. Closing guidance: First half of 2024